NeuroOne Medical Technologies Corporation Appoints Dr. Camilo Andres Diaz-Botia As Director of Electrode Development

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

NeuroOne Medical Technologies Corporation today announced the appointment of Dr. Camilo Andres Diaz-Botia, a highly experienced neural engineer whose work has focused on the development of technologies for bidirectional communication with the nervous system, as Director of Electrode Development.

Previously, Dr. Camilo Andres Diaz-Botia led the microfabrication process engineering team at Neuralink Corp., a Company founded by Elon Musk, working on developing a high bandwidth brain machine interface.

“We are thrilled to have such a highly regarded neural engineering expert to lead our development team,” says Dave Rosa, president and CEO, NeuroOne. “Camilo brings in-depth knowledge and expertise in the design of implantable thin film electrodes. His responsibilities and experience at Neuralink, from research and development to manufacturing, expand the depth and breadth of our capabilities to further develop NeuroOne’s portfolio of thin film electrode technology. As we continue to pursue our vision of developing combination diagnostic and therapeutic electrode technology, we expect Camilo’s leadership and experience will contribute significantly to helping us achieve these goals.”

At Neuralink Corp., Dr. Diaz-Botia led and mentored the process engineering team to deliver projects with unique microfabrication processes. Under his direction, the team built and designed novel processes for integration of thin film neural probes with brain machine interface systems.

Dr. Diaz-Botia earned a B.S. in Electrical Engineering from Universidad Nacional de Colombia and a Ph.D. in Bioengineering from the joint program at the University of California Berkeley and the University of California San Francisco. During his graduate studies, he conducted research on microfabricated thin film neural interfaces for chronic implants developing electrocorticography arrays with silicon carbide, a material suitable for long-term performance in harsh environments, and electrode arrays for minimally invasive subcortical recordings. He has authored and co-authored multiple peer reviewed scientific articles published in journals including Journal of Neural Engineering, Neuron and Lab-on-a-Chip.

Dr. Diaz-Botia states, “I believe NeuroOne’s focus on bringing thin-film devices to patients will have a significant impact in their overall clinical experience. For many years, thin film technologies have been utilized in academic settings and have matured enough to address a number of clinical needs today. I am excited to be a part of the ongoing development of NeuroOne’s thin film electrodes and furthering NeuroOne’s goal of making these devices commercially available.”

 

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles

Join our list

Subscribe to our mailing list and receive an end-of-week recap news and updates delivered right to your email inbox.